Abstract
Excessive cell proliferation contributes to the pathobiology of human diseases with a high health and socioeconomic impact, including cancer and vascular occlusive diseases (e.g., atherosclerosis, in-stent restenosis, transplant vasculopathy, and vessel bypass graft failure). Recent advances in the understanding of the molecular networks governing the hyperplastic growth of tumors and vascular obstructive neointimal lesions have provided new perspectives for preventive and therapeutic strategies against these disorders. Mammalian cell proliferation requires the activation of several cyclin-dependent protein kinases (CDKs). Postranslational activation of CDKs is a complex process that involves their association with regulatory subunits called cyclins. The activity of CDK / cyclin holoenzymes is negatively regulated through their interaction with members of the CDK family of inhibitory proteins (CKIs). Moreover, over fifty low molecular weight pharmacological CDK inhibitors that target the ATP-binding pocket of the catalytic site of CDKs have been identified. In this review, we will discuss the use of pharmacological and gene therapy strategies against CDK / cyclins in animal models and clinical trials of cancer and cardiovascular disease.
Keywords: cyclin-dependent kinase, cdk/cyclins, cdk family, ckI, cdk inhibitors
Current Pharmaceutical Biotechnology
Title: Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Volume: 4 Issue: 1
Author(s): C. Ivorra, H. Samyn, M. D. Edo, C. Castro, S. M. Sanz-González, A. Diez-Juan and V. Andres
Affiliation:
Keywords: cyclin-dependent kinase, cdk/cyclins, cdk family, ckI, cdk inhibitors
Abstract: Excessive cell proliferation contributes to the pathobiology of human diseases with a high health and socioeconomic impact, including cancer and vascular occlusive diseases (e.g., atherosclerosis, in-stent restenosis, transplant vasculopathy, and vessel bypass graft failure). Recent advances in the understanding of the molecular networks governing the hyperplastic growth of tumors and vascular obstructive neointimal lesions have provided new perspectives for preventive and therapeutic strategies against these disorders. Mammalian cell proliferation requires the activation of several cyclin-dependent protein kinases (CDKs). Postranslational activation of CDKs is a complex process that involves their association with regulatory subunits called cyclins. The activity of CDK / cyclin holoenzymes is negatively regulated through their interaction with members of the CDK family of inhibitory proteins (CKIs). Moreover, over fifty low molecular weight pharmacological CDK inhibitors that target the ATP-binding pocket of the catalytic site of CDKs have been identified. In this review, we will discuss the use of pharmacological and gene therapy strategies against CDK / cyclins in animal models and clinical trials of cancer and cardiovascular disease.
Export Options
About this article
Cite this article as:
Ivorra C., Samyn H., Edo D. M., Castro C., Sanz-González M. S., Diez-Juan A. and Andres V., Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease, Current Pharmaceutical Biotechnology 2003; 4 (1) . https://dx.doi.org/10.2174/1389201033377977
DOI https://dx.doi.org/10.2174/1389201033377977 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antimicrobial Peptides and Peptaibols, Substitutes for Conventional Antibiotics
Current Pharmaceutical Design The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews DNA Instability at Chromosomal Fragile Sites in Cancer
Current Genomics The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship
Current Medicinal Chemistry Overview of Coumarins and its Derivatives: Synthesis and Biological Activity
Letters in Organic Chemistry Xanthone Derivatives: New Insights in Biological Activities
Current Medicinal Chemistry Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry Phenothiazine: The Parent Molecule
Current Drug Targets Tumor Thermal Ablation Enhancement by Micromaterials
Current Drug Delivery Functions of Antimicrobial Peptides in Vertebrates
Current Protein & Peptide Science New Pharmacologic Horizons in the Treatment of Benign Prostatic Hyperplasia
Current Drug Therapy Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Role of Neuromodulation and Optogenetic Manipulation in Pain Treatment
Current Neuropharmacology The Potential Application of Biomaterials in Cardiac Stem Cell Therapy
Current Medicinal Chemistry Isothiocyanates in the Chemoprevention of Bladder Cancer
Current Drug Metabolism SRC: Regulation, Role in Human Carcinogenesis and Pharmacological Inhibitors
Current Pharmaceutical Design Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry A Dual Mode Pulsed Electro-Magnetic Cell Stimulator Produces Acceleration of Myogenic Differentiation
Recent Patents on Biotechnology Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals
Current Medical Imaging